| Autor: |
Ruberg FL; Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA.; Amyloidosis Center Boston University Chobanian & Avedisian School of Medicine Boston MA USA., Blaner WS; Department of Medicine Vagelos College of Physicians and Surgeons Columbia University Irving Medical Center New York NY., Chiuzan C; Feinstein Institute for Medical Research, Northwell Health New York NY., Connors LH; Amyloidosis Center Boston University Chobanian & Avedisian School of Medicine Boston MA USA.; Department of Pathology and Laboratory Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA., Einstein AJ; Seymour, Paul, and Gloria Milstein Division of Cardiology Department of Medicine Columbia University Irving Medical Center New York NY.; Department of Radiology Columbia University Irving Medical Center New York NY., Fine D; Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA., Helmke S; Seymour, Paul, and Gloria Milstein Division of Cardiology Department of Medicine Columbia University Irving Medical Center New York NY., Kurian D; Division of Cardiology Harlem Hospital Center New York City Health and Hospital Corporation New York NY., Pandey S; Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA., Raiszadeh F; Division of Cardiology Harlem Hospital Center New York City Health and Hospital Corporation New York NY., Rodriguez C; Seymour, Paul, and Gloria Milstein Division of Cardiology Department of Medicine Columbia University Irving Medical Center New York NY., Sabogal N; Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA., Teruya S; Seymour, Paul, and Gloria Milstein Division of Cardiology Department of Medicine Columbia University Irving Medical Center New York NY., Winburn M; Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA., Chung WK; Departments of Pediatrics and Medicine Columbia University Irving Medical Center New York NY., Cohn E; Hunter College City University of New York New York NY., Miller EJ; Section of Cardiovascular Medicine Department of Medicine Yale School of Medicine New Haven CT., Kelly JW; Department of Chemistry Skaggs Institute for Chemical Biology The Scripps Research Institute La Jolla CA., Maurer MS; Seymour, Paul, and Gloria Milstein Division of Cardiology Department of Medicine Columbia University Irving Medical Center New York NY. |
| Abstrakt: |
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is an important cause of heart failure in older individuals. Misfolding and deposition of transthyretin or prealbumin protein causes ATTR-CM in the context of a normal (wild-type) or variant TTR sequence. Variant ATTR-CM is most commonly caused by the substitution of valine for isoleucine at position 122 in transthyretin (Val122Ile or pV142I, almost exclusively observed in individuals of West African ancestry), demonstrated in 3.4% of self-identified Black individuals in the United States with an estimated 1.5 million carriers. Despite the large number of known pV142I carriers, the proportion of older Black patients with heart failure attributable to ATTR-CM remains unknown. Methods To address this knowledge gap, the SCAN-MP (Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations) study was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL139671) to enroll a targeted population of self-identified, community-dwelling Black or Caribbean Hispanic patients (many of whom are of West African ancestry) >60 years of age with heart failure and identify ATTR-CM by noninvasive nuclear imaging. The principal objective of SCAN-MP is to determine the prevalence of ATTR-CM in this population. Secondary objectives will explore TTR genotype, demographics, progression of variant versus wild-type ATTR-CM, and biochemical mechanisms of transthyretin amyloid fibril formation. Conclusions The SCAN-MP study is the largest, prospective study of cardiac amyloidosis in Black and Hispanic individuals. Both wild-type and variant ATTR-CM are now treatable with the US Food and Drug-approved drug tafamidis. The insights gained from SCAN-MP are likely to improve those at risk for or afflicted with ATTR-CM. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03812172. |
Plný text